National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

Understanding Cancer Series: Angiogenesis
< Back to Main
In English En español
    Posted: 01/28/2005    Reviewed: 09/01/2006
Page Options
Print This Page  Print This Page
Print This Document  Print This Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
View/Print PDF  View/Print PDF
View/Print PowerPoint  View/Print PowerPoint
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
Questions about cancer?

1-800-4-CANCER
Quit Smoking Today
NCI Highlights
Office of Biorepositories and Biospecimen Research

The Nation's Investment in Cancer Research FY 2010

Report to the Nation Finds Continued Declines in Cancer Rates
Slide 20 : Angiogenesis Inhibitors in the Treatment of Human Cancer previousnext

Researchers are now asking if inhibiting angiogenesis can slow down or prevent the growth and spread of cancer cells in humans.

To answer this question, almost two dozen angiogenesis inhibitors are currently being tested in cancer patients. The inhibitors being tested fall into several different categories, depending on their mechanism of action. Some inhibit endothelial cells directly, while others inhibit the angiogenesis signaling cascade or block the ability of endothelial cells to break down the extracellular matrix.

Angiogenesis Inhibitors in the Treatment of Human Cancer

< Previous  |  Index  |  Next Slide >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov